References

  1. Davis LL, Wisniewski SR, Howland RH, et al. Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. Drug Alcohol Depend. 2010;107(2-3):161-170.
  2. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41(11):1284-1292.
  3. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613.
  4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing, 2013.
  5. New York State Department of Health AIDS Institute. Mental health screening: a quick reference guide for HIV primary care clinicians. http://www.hivguidelines.org/. Accessed on September 23, 2014
  6. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25(1):119-142.
  7. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.
  8. Sussman N. Understanding STAR*D findings. Prim Psychiatry. 2006;13:12-13.
  9. Rubinow DR. Treatment strategies after SSRI failure–good news and bad news. N Engl J Med. 2006;354(12):1305-1307.
  10. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
  11. Tsai AC, Karasic DH, Hammer GP, et al. Directly observed antidepressant medication treatment and HIV outcomes among homeless and marginally housed HIV-positive adults: a randomized controlled trial. Am J Public Health. 2013;103(2):308-315.
  12. Faragon J, Cournos F, Wainberg ML. Psychiatric medications and HIV antiretrovirals: a drug interaction guide for clinicians. 2013;3rd., NY/NJ AIDS Education and Training Center.
  13. Galvan FH, Bing EG, Fleishman JA, et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV Cost and Services Utilization Study. J Stud Alcohol. 2002;63:179-186.
  14. Cook RL, Sereika SM, Hunt SC, Woodward WC, Erlen JA, Conigliaro J. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med. 2001;16(2):83-88.
  15. Wagner JH, Justice AC, Chesney M, Sinclair G, Weissman S, Rodriguez-Barradas M. Patient- and provider-reported adherence: toward a clinically useful approach to measuring antiretroviral adherence. J Clin Epidemiol. 2001;54 Suppl 1:S91-S98.
  16. Lazo M, Gange SJ, Wilson TE, et al. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis. 2007;45(10):1377-1385.
  17. Conigliaro J, Gordon AJ, McGinnis KA, Rabeneck L, Justice AC. How harmful is hazardous alcohol use and abuse in HIV infection: do health care providers know who is at risk? JAIDS. 2003;33(4):521-525.
  18. Justice AC, Wagner JH, Fusco GP et al. Liver function tests independently predict survival. [Abstract MoOrB1058.] XIV International AIDS Conference. July 7-12, 2002; Barcelona, Spain
  19. Kalichman SC, Rompa D, Cage M. Sexually transmitted infections among HIV seropositive men and women. Sex Transm Infect. 2000;76(5):350-354.
  20. Stein MD, Anderson B, Charuvastra A, Friedmann PD. Alcohol use and sexual risk taking among hazardously drinking drug injectors who attend needle exchange. Alcohol Clin Exp Res. 2001;25(10):1487-1493.
  21. Samet JH, Cheng DM, Libman H, Nunes DP, Alperen JK, Saitz R. Alcohol consumption and HIV disease progression. JAIDS. 2007;46(2):194-199.
  22. Tsai J, Ford ES, Li C, Zhao G. Past and current alcohol consumption patterns and elevations in serum hepatic enzymes among US adults. Addict Behav. 2012;37(1):78-84.
  23. Miguez-Burbano MJ, Lewis JE, Fishman J, Asthana D, Malow RM. The influence of different types of alcoholic beverages on disrupting highly active antiretroviral treatment (HAART) outcome. Alcohol Alcohol. 2009;44(4):366-371.
  24. Samet JH, Horton NJ, Meli S, Freedberg KA, Palepu A. Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol Clin Exp Res. 2004;28(4):572-577.
  25. Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. JAIDS. 2006;43(4):411-417.
  26. Davis KC, Hendershot CS, George WH, Norris J, Heiman JR. Alcohol’s effects on sexual decision making: an integration of alcohol myopia and individual differences. J Stud Alcohol Drugs. 2007;68(6):843-851.
  27. Cooper ML. Alcohol use and risky sexual behavior among college students and youth: evaluating the evidence. J Stud Alcohol Suppl. 2002;(14):101-117.
  28. Dermen KH, Cooper ML. Inhibition conflict and alcohol expectancy as moderators of alcohol’s relationship to condom use. Exp Clin Psychopharmacol. 2000;8(2):198-206.
  29. Koblin B, Chesney M, Coates T. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. Lancet. 2004;364(9428):41-50.
  30. Ammon L, Sterling S, Mertens J, Weisner C. Adolescents in private chemical dependency programs: who are most at risk for HIV? J Subst Abuse Treat. 2005;29(1):39-45.
  31. Woods WJ, Lindan CP, Hudes ES, Boscarino JA, Clark WW, Avins AL. HIV infection and risk behaviors in two cross-sectional surveys of heterosexuals in alcoholism treatment. J Stud Alcohol. 2000;61(2):262-266.
  32. Kim S, De La Rosa M, Trepka MJ, Kelley M. Condom use among unmarried students in a Hispanic-serving university. AIDS Educ Prev. 2007;19(5):448-461.
  33. Mayer KH, Mimiaga MJ, Cohen D, et al. Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. JAIDS. 2008;47(4):494-499.
  34. New York City Department of Health and Mental Hygiene. Alcohol use and risky sex in New York City. http://www.nyc.gov/html/doh/downloads/pdf/survey/survey-2008alcohol.pdf. Accessed on August 11, 2014
  35. Stein M, Herman DS, Trisvan E, Pirraglia P, Engler P, Anderson BJ. Alcohol use and sexual risk behavior among human immunodeficiency virus-positive persons. Alcohol Clin Exp Res. 2005;29(5):837-843.
  36. Theall KP, Clark RA, Powell A, Smith H, Kissinger P. Alcohol consumption, ART usage and high-risk sex among women infected with HIV. AIDS Behav. 2007;11(2):205-215.
  37. Schiff ER. Hepatitis C and alcohol. Hepatology. 1997;26(3 Suppl 1):39S-42S.
  38. Chen CM, Yoon YH, Yi HY, Lucas DL. Alcohol and hepatitis C mortality among males and females in the United States: a life table analysis. Alcohol Clin Exp Res. 2007;31(2):285-292.
  39. Monto A, Patel K, Bostrom A, et al. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology. 2004;39(3):826-834.
  40. Lieber CS. Alcohol and hepatitis C. Alcohol Res Health. 2001;25(4):245-254.
  41. Singal AK, Anand BS. Mechanisms of synergy between alcohol and hepatitis C virus. J Clin Gastroenterol. 2007;41(8):761-772.
  42. Brown RL, Leonard T, Saunders LA, Papasouliotis O. A two-item conjoint screen for alcohol and other drug problems. J Am Board Fam Pract. 2001;14(2):95-106.
  43. French MT, Roebuck MC, McGeary KA, Chitwood DD, McCoy CB. Using the drug abuse screening test (DAST-10) to analyze health services utilization and cost for substance users in a community-based setting. Subst Use Misuse. 2001;36(6-7):927-946.
  44. Torrens M, Fonseca F, Mateu G, Farre M. Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. Drug Alcohol Depend. 2005;78(1):1-22.
  45. Whitlock EP, Polen MR, Green CA, Orleans T, Klein J. Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2004;140(7):557-568.
  46. Aharonovich E, Hatzenbuehler ML, Johnston B, et al. A low-cost, sustainable intervention for drinking reduction in the HIV primary care setting. AIDS Care. 2006;18(6):561-568.
  47. Hasin DS, Aharonovich E, O’Leary A, et al. Reducing heavy drinking in HIV primary care: a randomized trial of brief intervention, with and without technological enhancement. Addiction. 2013;108(7):1230-1240.
  48. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789-1799.
  49. Clifford DB, Ances BM. HIV-associated neurocognitive disorder. Lancet Infect Dis. 2013;13(11):976-986.
  50. Dore GJ, McDonald A, Li Y, Kaldor JM, Brew BJ. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. 2003;17(10):1539-1545.
  51. Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007;21(14):1915-1921.
  52. Sacktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol. 2002;8:136-142.
  53. McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology. 1993;43(11):2245-2252.
  54. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17(1):3-16.
  55. Joska JA, Gouse H, Paul RH, Stein DJ, Flisher AJ. Does highly active antiretroviral therapy improve neurocognitive function? A systematic review. J Neurovirol. 2010;16(2):101-114.
  56. Sacktor N, Skolasky RL, Seaberg E, et al. Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study. Neurology. 2016;86(4):334-340.
  57. Heaton RK, Clifford DB, Franklin DRJ, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75(23):2087-2096.
  58. Hopkins HIV Report. Minor cognitive motor disorder: Does it really exist? http://www.thebody.com/jh/hivrept/nov96/minor.html. Accessed on August 11, 2014
  59. Sakamoto M, Marcotte TD, Umlauf A, et al. Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort. JAIDS. 2013;62(1):36-42.
  60. Davis HF, Skolasky RL, Jr., Selnes OA, Burgess DM, McArthur JC. Assessing HIV-associated dementia: modified HIV dementia scale versus the Grooved Pegboard. AIDS Read. 2002;12(1):29-31, 38.
  61. Lu H, Brew BJ, Siefried KJ, Draper B, Cysique LA. Is the HIV dementia scale a reliable tool for assessing HIV-related neurocognitive decline? J AIDS Clin Res. 2013;5:269.
  62. Hinkin CH, Castellon SA, Hardy DJ, Farinpour R, Newton T, Singer E. Methylphenidate improves HIV-1-associated cognitive slowing. J Neuropsychiatry Clin Neurosci. 2001;13(2):248-254.